Uloric Gout Medication Linked to Increased Risk of Heart-Related Deaths
After reviewing data from a safety clinical trial, the U.S. Food and Drug Administration (FDA) recently announced that Uloric (febuxostat), a medication designed to treat the symptoms of gout, is linked to an increased risk of heart-related deaths and deaths of all causes.
As a result, the FDA now requires Uloric to feature a Boxed Warning—its most prominent and urgent warning. In addition, the FDA will limit approved uses of the medication to patients who had poor or negative responses to allopurinol, another medication designed to treat gout.
If you or someone you love experienced cardiovascular complications, stroke, or heart-related death as a result of Uloric, you may be entitled to significant compensation. Contact the drug injury lawyers at Ferrer, Poirot & Wansbrough today for a free case review. Dial (800) 210-8503 now to get started.
Common Uloric-Related Complications
Gout is an arthritis-related condition characterized by pain and swelling in affected joints due to excess levels of uric acid. Uloric was approved for treatment of gout by the FDA in 2009, and it’s designed to improve patients’ symptoms by reducing levels of uric acid in their bloodstreams.
The FDA urges people who take Uloric to seek emergency medical attention if they experience any of the following symptoms:
- Chest pain
- Shortness of breath
- Rapid or irregular heartbeat
- Numbness or weakness on one side of the body
- Difficulty talking
- Sudden severe headache
Patients with a history of heart problems or stroke should talk to their doctors about the risks and benefits of using Uloric due to its association with cardiac-related deaths. The FDA also recommends that patients currently taking Uloric continue to do so until they speak with their doctors about their options, as ceasing the medication can worsen gout symptoms.
Contact the drug injury attorneys at Ferrer, Poirot & Wansbrough if you or your loved one experienced cardiovascular complications while taking Uloric. It’s our goal to help you get maximum compensation for your injury-related expenses and pain and suffering. Call us today at (800) 210-8503 for a free consultation.
What Are the Risks of Uloric Compared to Other Gout Medications?
When the FDA approved Uloric in 2009, it included a warning with the medication concerning the potential for cardiovascular events. It also required Uloric’s manufacturer, Takeda Pharmaceuticals, to conduct a safety clinical trial to evaluate its risks.
The trial involved 6,000 gout patients who were treated with either Uloric or allopurinol. Data recently obtained from the safety trial indicated that patients treated with Uloric had a higher risk of suffering heart-related deaths and deaths of all causes than patients treated with allopurinol.
Did You or Someone You Love Suffer a Uloric-Related Heart Injury? Call Us Today.
The drug injury lawyers at Ferrer, Poirot & Wansbrough are here to help families and individuals who were affected by Uloric’s heart-related risks.
If you or someone you love suffered any of the following injuries, we want to speak with you:
- Heart-related death
- Non-deadly heart attack
- Non-deadly stroke
- Reduced blood supply to the heart requiring medical intervention (unstable angina)
It’s our goal to help you get maximum compensation for your medical bills, lost wages, and other heart injury-related expenses. Contact our law firm today to find out how we may be able to help by calling us at (800) 210-8503 or by requesting a free case review.
Ferrer, Poirot & Wansbrough is not associated with, sponsored by, or affiliated with the U.S. Food and Drug Administration or Takeda Pharmaceuticals.